Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. [electronic resource]
Producer: 20180201Description: 900-906 p. digitalISSN:- 1525-1438
- Adult
- Aged
- Aged, 80 and over
- Anastrozole
- Antineoplastic Agents, Hormonal -- adverse effects
- Carcinoma, Ovarian Epithelial
- Drug Resistance, Neoplasm
- Female
- Humans
- Immunohistochemistry
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasms, Glandular and Epithelial -- drug therapy
- Nitriles -- adverse effects
- Organoplatinum Compounds -- pharmacology
- Ovarian Neoplasms -- drug therapy
- Prospective Studies
- Quality of Life
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Tissue Array Analysis
- Triazoles -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.